(International Union Against Tuberculosis and Lung Disease, 2018-09-01) Mukora, R.; Tlali, M.; Monkwe, S.; Charalambous, S.; Karat, Aaron S.; Fielding, K. L.; Grant, A. D.; Vassall, A.
INTRODUCTION: The World Health Organization recommends point-of-care (POC) lateral flow urine lipoarabinomannan (LF-LAM) for tuberculosis (TB) diagnosis in selected human immunodeficiency virus (HIV) positive people. South Africa had 438 000 new TB episodes in 2016, 58.9% of which were contributed by HIV-positive people. LF-LAM is being considered for scale-up in South Africa.
